Pulmonary Rehabilitation for COPD
(RISE Trial)
Trial Summary
What is the purpose of this trial?
Chronic obstructive pulmonary disease (COPD), one of the leading causes of death in the US, disproportionately affects low socioeconomic communities. While few interventions effectively modify the course of COPD and improve outcomes, pulmonary rehabilitation is the one notable exception. However, implementation of this resource-intensive program in real-life settings, and in particular, for underserved communities, has proven to be challenging. Safety-net centers that serve primarily under-insured populations lack financial resources to provide pulmonary rehabilitation. The 10-week COPD Wellness and Plus+ Program directly addresses this gap, and yet, programs like these do not automatically lead to improved outcomes, which leads to the implementation of a Health Advocates program to address participant's social needs and barriers to healthcare.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should be currently prescribed COPD medication(s), which suggests you may continue your current COPD medications.
What data supports the effectiveness of the treatment COPD Wellness, Pulmonary Rehabilitation, COPD Wellness and Plus+ Program, COPD Wellness Plus+, Pulmonary Rehabilitation, COPD Rehabilitation, COPD Wellness and Plus+ Program, Usual Care, Standard Care, Conventional Care for COPD?
Is pulmonary rehabilitation safe for people with COPD?
How is the COPD Wellness Plus+ treatment different from other COPD treatments?
The COPD Wellness Plus+ treatment is unique because it integrates pulmonary rehabilitation with a focus on self-management education and includes a domiciliary (home-based) component with regular phone support from a respiratory team, which may help reduce the frequency of acute exacerbations and improve overall quality of life.110111213
Research Team
Neeta Thakur, MD, MPH
Principal Investigator
University of California, San Francisco
Eligibility Criteria
This trial is for adults aged 40-90 with physician-diagnosed COPD, a specific lung function score (FEV1/FVC ≤ 0.7 and FEV1% <80%), and a history of exacerbations. They must be on COPD meds, able to exercise with their legs, not have had recent severe illness or rehab, and be SFHN patients.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo the 10-week COPD Wellness and Plus+ Program, which includes pulmonary rehabilitation and social navigation through Health Advocates
Follow-up
Participants are monitored for changes in medication adherence, functional status, symptom burden, and quality of life
Long-term Follow-up
Assessment of health system adoption and maintenance of the intervention
Treatment Details
Interventions
- COPD Wellness
- COPD Wellness Plus+
- Usual Care
COPD Wellness is already approved in European Union, United States, Canada for the following indications:
- Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Obstructive Pulmonary Disease (COPD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator